GAP-Net Site El Faro Health and Therapeutics’ Dr. James Falcon was interviewed about the new research center. Starr County, a rural area along the Texas-Mexico border, has one of the highest rates of Alzheimer’s disease in the country. It’s not clear why. But physicians at a new research and treatment center in the area hope to […]
GAP President John Dwyer was quoted in AlzForum about the Centers for Medicare and Medicaid Services (CMS) National Coverage Decision (NCD) to only cover the drug Aduhlem for those in enrolled in a qualifying clinical trial. The verdict is in—but what now? The Centers for Medicare and Medicaid Services will only cover aducanumab in the context of […]
GAP President John Dwyer spoke about the Bio-Hermes study and why enrolling minority populations are a priority. Metro Orlando clinical trial hopes to speed up Alzheimer’s diagnoses for minorities Black people are twice as likely as white people to develop Alzheimer’s disease — Latinx people, 1.5 times as likely. But barriers including access to health […]
GAP-Net sites Baylor College of Medicine Alzheimer’s Disease and Memory Disorders Center and the Lou Ruvo Center for Brain Health at the Cleveland Clinic in Las Vegas are collaborating on a film project to bring awareness of the prevalence of Alzheimer’s disease in the Latino community. Assistant director Aaron Thomas slams the clapperboard Saturday to […]
GAP-Net site El Faro Health & Therapeutics was featured in the Houston Chronicle. The disease took Noemi Fleming’s elderly mother slowly, the first hints in repeated anecdotes or phrases. Then misplaced keys and bills. Then, Fleming caught her mother walking outside in the middle of the night, looking for the newspaper. “Mama, it’s 1 o’clock […]
Washington, D.C. (April 7, 2022) – “Today, the Centers for Medicare and Medicaid Services (CMS) issued its final coverage ruling for an entire class of Alzheimer’s drugs. At its core, this National Coverage Decision (NCD) is not very different here from a flat-out denial of coverage. CMS continues to treat all Alzheimer’s patients differently than any other class […]
Modeled after DARPA, ARPA-H will incentivize innovative approaches to address some of America’s deadliest diseases Washington, D.C. (March 30, 2022) – A group of leading scientists and patient advocates today applauded the Biden Administration and Congress for making the Advanced Research Projects Agency for Health (ARPA-H) a reality. This new agency is designed to empower […]
GAP President John Dwyer was quoted in Pink Sheet in regard to the Centers for Medicare and Medicaid Services’ proposed National Coverage Decision. The Centers for Medicare and Medicaid Services’ proposed eligibility criteria for the research sites capable of conducting clinical trials for monoclonal antibody drugs for Alzheimer’s disease could be met in just 28 […]
GAP President John Dwyer, on behalf of the organization, joined other Alzheimer’s advocates in Washington D.C. for the ‘Rally for Access’ on March 15, 2022. The ‘Rally for Access’ gathered these organizations to remind the public what is at stake if the Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) is accepted. […]
CMS FAILS TO FAIRLY EVALUATE ALZHEIMER’S TREATMENTS Washington, D.C. (March 23, 2022) — Adding to the growing number of advocates calling on the U.S. Centers for Medicare and Medicaid Services (CMS) to reconsider an unprecedented National Coverage Determination (NCD) that discriminates against 6 million people with Alzheimer’s disease, U.S. Senators Mark R. Warner (D-VA) and […]
GAP-Net Site Charter Research’s Jeff Pohlig, CEO, wrote an Op-Ed about how volunteering can improve your health and your community. Unfortunately, over 90% of research studies are delayed because of slow recruitment. These delays may be affecting the treatment of your neighbor, loved one, co-worker or friend. Floridians facing Alzheimer’s need clinical trial volunteers to […]
Washington, D.C. (March 1, 2022) – “He did it again. From his victory speech in November 2020 and then again in his initial address to the nation in 2021, and then tonight in his most major address yet unveiling his ‘Unity Agenda,’ President Biden put Alzheimer’s disease near the top of the U.S. national public […]
Global Alzheimer’s Platform Foundation® Honorees Include the First Canadian Recipient, Advocate to Veterans, Caregiver, and First Honoree with Parkinson’s Disease Contact: Andi Zucchi – andizucchi@rational360.com, 360-927-8767 Washington, DC (February 23, 2022) – The Global Alzheimer’s Platform Foundation (GAP) is honoring four clinical trial volunteers with 2021 National Citizen Scientist Awards. This year’s recipients include the […]
GAP President John Dwyer was featured in Pink Sheet talking about the cost of Aduhelm affecting the Centers for Medicare and Medicaid Services NCD. US Medicare coverage policy is supposed to be fenced off from considerations about the cost of a prescription drug (or other item or service). But the notion that the cost of […]
MedVadis Research will join the Global Alzheimer’s Platform Foundation® Network (GAP-Net) of more than 100 global clinical trial sites Washington, D.C. (February 10, 2022) – The Global Alzheimer’s Platform Foundation® (GAP) announced that MedVadis Research has joined its network of more than 100 global clinical trial sites (GAP-Net), a team of leading academic and private […]
Dwyer calls on Centers for Medicare & Medicaid Services to provide coverage for the entire class of mAb drugs approved by the Food & Drug Administration and future drugs yet to be approved Washington, D.C. (February 11, 2022) – The Centers for Medicare & Medicaid Services (CMS) proposed plan to limit coverage of an entire […]
Experts voice concerns over pre-judging promising treatments in the pipeline Today, five top Alzheimer’s clinicians and researchers called into question the preliminary proposal from the Centers for Medicare and Medicaid Services (CMS) to limit coverage FDA-approved monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease. The CMS proposal would alter the course of […]
Being Patient answers some common questions regarding the Centers for Medicare and Medicaid Services (CMS) proposal, and GAP President John Dwyer mentions how this could affect future Alzheimer’s trials and treatments. The CMS proposed a plan that could strip Alzheimer’s drug Aduhelm of public Medicare coverage. The result was widespread confusion. We clarify some aspects […]
GAP President John Dwyer was quoted in NJ.com about the future of Alzheimer’s treatments if the CMS National Coverage Decision (NCD) proposal is approved. Every day in this country, an estimated 1,000 people progress from moderate Alzheimer’s dementia to the final and most severe stage of the disease. That’s a grim statistic in its own […]
New survey finds that 83% of neurologists believe that the safety and efficacy of an entire class of drugs should not be determined by the results of one medication. Washington, D.C. (February 2, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of […]
Despite highest incidence of dementia, this is the first-ever Alzheimer’s clinical study in Starr County Rio Grande City, TX (February 2, 2022) –El Faro Health & Therapeutics will begin screening volunteers for its first-ever clinical trial in Rio Grande City, TX. The Bio-Hermes Study, sponsored by the Global Alzheimer’s Platform Foundation® (GAP), seeks volunteers with or […]
GAP President John Dwyer spoke to Pink Sheet about the CMS NCD proposal. The Centers for Medicare and Medicaid Service’s proposal to allow Medicare to pay for amyloid-directed monoclonal antibody drugs for Alzheimer’s only when they are used in randomized controlled clinical trials could significantly curtail access to the drugs for at least four years, […]
Washington, D.C. (January 27, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, applauded the announcement today by Biogen Inc. that it would ensure that at least 18 percent of participants in its FDA mandated study will […]
GAP President John Dwyer was quoted in Politico talking about the difficulty of having a diverse population pool in Alzheimer’s clinical trial, and how unlike that is to achieve if the CMS proposal is approved. Drugmakers and patient advocacy groups are waging a campaign to cast Medicare officials as villains after the program limited coverage […]